Stock 688566 JIANGSU JIBEIER PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Jibeier Pharmaceutical Co., Ltd.

Equities

688566

CNE100004041

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-13 pm EDT 		5-day change 1st Jan Change
24.49 CNY -1.88% Intraday chart for Jiangsu Jibeier Pharmaceutical Co., Ltd. +1.70% -21.98%
Jun. 05 Jiangsu Jibeier Pharmaceutical Co., Ltd. announced that it has received CNY 198.161716 million in funding from a group of investors CI
May. 21 Jibeier Pharmaceutical Gets Patents for Two Products MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 4,266 4,004 5,935 4,631 - -
Enterprise Value (EV) 1 4,266 4,004 5,935 4,631 4,631 4,631
P/E ratio 37.4 x 25.8 x 26.8 x 16.4 x 13.5 x 10.8 x
Yield - - - - - -
Capitalization / Revenue - 6.12 x 6.89 x 4.34 x 3.51 x 2.91 x
EV / Revenue - 6.12 x 6.89 x 4.34 x 3.51 x 2.91 x
EV / EBITDA - 21 x 22.7 x 14.5 x 13.8 x 9.75 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 2.37 x 3.12 x 2.2 x 1.92 x 1.71 x
Nbr of stocks (in thousands) 186,942 186,942 189,084 189,084 - -
Reference price 2 22.82 21.42 31.39 24.49 24.49 24.49
Announcement Date 4/27/22 2/27/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 654.7 860.9 1,066 1,317 1,592
EBITDA 1 - 190.2 261.4 318.6 336.6 475.2
EBIT 1 - 176.4 249.1 319.3 391.7 486.2
Operating Margin - 26.94% 28.94% 29.96% 29.74% 30.54%
Earnings before Tax (EBT) 1 - 174.5 247.5 317.9 389.9 484.6
Net income 1 114.9 154.7 219.1 281.4 341.7 429
Net margin - 23.62% 25.45% 26.41% 25.93% 26.95%
EPS 2 0.6100 0.8300 1.170 1.490 1.810 2.270
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 4/27/22 2/27/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 9.36% 12.2% 13.4% 14.2% 15.9%
ROA (Net income/ Total Assets) - - 10.5% 11% 11.7% -
Assets 1 - - 2,087 2,558 2,920 -
Book Value Per Share 2 - 9.030 10.10 11.10 12.70 14.30
Cash Flow per Share 2 - 0.8100 0.8400 2.780 1.600 2.070
Capex 1 - - 357 185 205 -
Capex / Sales - - 41.51% 17.36% 15.56% -
Announcement Date 4/27/22 2/27/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jiangsu Jibeier Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.49
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
JIANGSU JIBEIER PHARMACEUTICAL CO., LTD. Stock Jiangsu Jibeier Pharmaceutical Co., Ltd.
-21.98% 651M
MERCK KGAA Stock Merck KGaA
+19.36% 80.64B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.93% 9.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.06% 4.68B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-22.01% 4.53B
YUHAN CORPORATION Stock Yuhan Corporation
+8.28% 4.06B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-26.61% 2.21B
INDIVIOR PLC Stock Indivior PLC
+11.22% 2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.64% 2B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-42.69% 1.82B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688566 Stock
  4. Financials Jiangsu Jibeier Pharmaceutical Co., Ltd.